RAS Pathway Drug Competition And Financing Risks Will Dominate Yet Long-Term Potential Remains

AnalystLowTarget

Analyst Low Target compiles bearish analysts opinions to create narratives which represent one standard deviation below the consensus price target, using forecasted revenue and earnings figures, as well as the transcripts of earnings calls.

Published

14 Dec 25

Updated

26 Jun 26

Views

Not Invested

Shared on 26 Jun 26

Fair value Decreased 37%

VSTM: Future KRAS Data And Pancreatic Trial Progress Will Drive Repricing

Verastem’s outlook looks more mixed as analysts cut what they think the company is worth, pointing to tougher competition and higher pressure to prove its drugs stand out. At the same time, fresh early results and new trial progress in hard-to-treat cancers could be the next big factor that changes how investors view the story.

6 views

Fair Value vs Share Price

US$8.85

vs US$5.7535.0% undervalued

76.3%

Revenue growth

18.9%

Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Verastem

Fair value estimate changes
Narrative and analyst updates
Key company announcements

Company analysis

Undervalued with excellent balance sheet.

Market capUS$529.9m

PB6.2x

Estimated Growth40.4%

Dividend YieldN/A

Full analysis

CEO & management

Daniel Paterson

CEO

2.5yrs

CEO Tenure

A development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States.